Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

COVIDecode

Financiado

Cerrado

Interrogating RNA-protein interactions underlying SARS-CoV-2 infection and antiv...

Interrogating RNA-protein interactions underlying SARS-CoV-2 infection and antiviral defense The global COVID-19 pandemic underscores the need to better understand its causative agent, SARS-CoV-2, and the various other emerging viruses threatening human health. Like many human viruses, SARS-CoV-2 utilizes RNA as its repli... ver más

30/04/2027

GUF

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

JOHANN WOLFGANG GOETHEUNIVERSITAET FRANKFURT... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-05-01

ERC-2021-STG: ERC STARTING GRANTS Scope:Objectives

I+D

Cerrada hace 3 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

GUF

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-124566OB-I00 ANALISIS DE INTERACCIONES ARN-PROTEINA Y ARN-ARN EN VIRUS DE... 145K€ Cerrado

AVFLU Interactions between avian and influenza virus proteins 100K€ Cerrado

ER and Infection ER Function In Virus Infection 183K€ Cerrado

PRE2021-098900 EL PAPEL DE LAS INTERACCIONES PROTEINA-PROTEINA Y PROTEINA-A... 101K€ Cerrado

RNAFLU EFFECT OF NATURAL VIRAL RNA SEQUENCE VARIATION ON INFLUENZA... 2M€ Cerrado

VirIm Dynamics and heterogeneity of early viral infection 2M€ Cerrado

Duración del proyecto: 59 meses Fecha Inicio: 2022-05-01
Fecha Fin: 2027-04-30

Líder del proyecto

JOHANN WOLFGANG GOETHEUNIVERSITAET FRANKFURT... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The global COVID-19 pandemic underscores the need to better understand its causative agent, SARS-CoV-2, and the various other emerging viruses threatening human health. Like many human viruses, SARS-CoV-2 utilizes RNA as its replicated genetic material and its template for translating the virus's proteins. Ongoing research into SARS-CoV-2 and other RNA viruses has largely focused on understanding the function of their encoded proteins, revealing key roles in host cell entry, viral replication, and immune suppression. In contrast, little is known about the set of viral RNAs and how they interact with host machinery as part of a virus's replication cycle in infected cells. My group discovered a large collection of viral and host proteins that bind the genomic and subgenomic RNAs of SARS-CoV-2 during infection. This collection provides an excellent starting point to work toward the goal of my proposed ERC Starting Grant project: decoding how these interactions shape the viral RNA life cycle and contribute to antiviral defense mechanisms. My overarching hypothesis is that SARS-CoV-2 dynamically modulates RNA-protein interactions in the host to facilitate functions of genomic and subgenomic viral RNAs at different stages of the replication cycle. To test this hypothesis, I have devised three research objectives: 1) Decode mechanisms of host-mediated control over the life cycle of SARS-CoV-2 RNAs. 2) Map with temporal resolution which host cell proteins engage each SARS-CoV-2 RNA type. 3) Elucidate the role of host proteins that moonlight as RNA binders in SARS-CoV-2 infections. If successful, this project will identify novel pro- and antiviral host factors in SARS-CoV-2 infections and reveal underlying RNA regulatory mechanisms. In turn, these insights will provide an RNA-centric view of viral infections and identify candidate factors and pathways as therapeutic targets to treat viral diseases.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores